Yuval Cohen Corbus Pharmaceuticals Holdings, Inc. (CRBP) insider trading activity

Yuval Cohen is Chief Executive Officer of Corbus Pharmaceuticals Holdings, Inc.. Currently has a direct ownership of 188,187 shares of CRBP, which is worth approximately $2.08 Million. The most recent transaction as insider was on Jan 14, 2026, when has been sold 50,000 shares (Common Stock, par value $0.0001 per share) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 188K

36.18% 3M change

143.7% 12M change

Total Value Held $2.08 Million

Yuval Cohen Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 14 2026	BUY Grant, award, or other acquisition	-	50,000 Added 20.99%	188,187 Common Stock, par valu...
Oct 27 2025	SELL Open market or private sale	$153,797 $17.14 p/Share	8,973 Reduced 6.1%	138,187 Common Stock, par valu...
Oct 27 2025	BUY Exercise of conversion of derivative security	$38,224 $4.26 p/Share	8,973 Added 5.75%	147,160 Common Stock, par valu...
Oct 24 2025	SELL Open market or private sale	$317,406 $17.01 p/Share	18,660 Reduced 11.9%	138,187 Common Stock, par valu...
Oct 24 2025	BUY Exercise of conversion of derivative security	$79,491 $4.26 p/Share	18,660 Added 10.63%	156,847 Common Stock, par valu...
Feb 14 2025	SELL Open market or private sale	$62,493 $8.76 p/Share	7,134 Reduced 4.91%	138,187 Common Stock, par valu...
Jan 31 2025	BUY Grant, award, or other acquisition	-	68,100 Added 31.91%	145,321 Common Stock, par valu...

Jun 18 2024	SELL Open market or private sale	$968,901 $42.24 p/Share	22,938 Reduced 22.9%	77,221 Common Stock, par valu...
Jun 18 2024	BUY Exercise of conversion of derivative security	$254,035 $16.12 p/Share	15,759 Added 15.38%	86,722 Common Stock, par valu...
Jun 17 2024	SELL Open market or private sale	$510,960 $46.02 p/Share	11,103 Reduced 11.63%	84,400 Common Stock, par valu...
Jun 17 2024	BUY Exercise of conversion of derivative security	$190,194 $17.13 p/Share	11,103 Added 11.41%	86,170 Common Stock, par valu...
Jun 14 2024	SELL Open market or private sale	$1,470,833 $50.17 p/Share	29,317 Reduced 25.78%	84,400 Common Stock, par valu...
Jun 14 2024	BUY Exercise of conversion of derivative security	$269,130 $9.18 p/Share	29,317 Added 23.23%	96,887 Common Stock, par valu...
Feb 12 2024	BUY Grant, award, or other acquisition	-	73,947 Added 46.7%	84,400 Common Stock, par valu...
Jan 26 2024	BUY Exercise of conversion of derivative security	$35,679 $4.97 p/Share	7,179 Added 50.0%	7,179 Common Stock
Aug 10 2022	BUY Open market or private purchase	$988 $0.26 p/Share	3,800 Added 3.72%	98,230 Common Stock
May 16 2022	BUY Open market or private purchase	$2,625 $0.25 p/Share	10,500 Added 10.01%	94,430 Common Stock
Mar 09 2022	BUY Open market or private purchase	$3,182 $0.37 p/Share	8,600 Added 9.29%	83,930 Common Stock
Nov 11 2020	BUY Open market or private purchase	$5,130 $1.21 p/Share	4,240 Added 5.33%	75,330 Common Stock

Yuval Cohen

Chief Executive Officer

Norwood, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CRBP shares.

Notify only if

Value

Insider Trading

Get notified when an Corbus Pharmaceuticals Holdings, Inc. insider buys or sells CRBP shares.

Notify only if

Operation

Value

Type

News

Receive news related to Corbus Pharmaceuticals Holdings, Inc.

Track Activities on CRBP

Account